TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically documented colorectal cancer that has been curatively resected, including: Dukes' A/B1 (T1-2, N0, M0) Dukes' B2/C (T3, N0, M0 and any T, N1, M0) disease-free more than 5 years post-resection Colonoscopy to the cecum (or small bowel anastomosis) with removal of all polyps required within 4 months of entry Preparation must be adequate to visualize mucosa and discern the presence of no further polyps No familial polyposis (more than 100 polyps at time of resection) No history of inflammatory bowel disease including ulcerative colitis or Crohn's disease~PATIENT CHARACTERISTICS: Age: 30 to under 75 Performance status: Physician's assessment of good general health required Life expectancy: At least 5 years Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Cardiovascular: No NYHA class III/IV status No history of angina No history of MI No history of stroke or TIAs No peripheral vascular disease No bleeding diathesis including hemorrhagic stroke No prophylactic aspirin for cardiovascular disease Other: No documented peptic ulcer disease within past 15 years No aspirin sensitivity including: Aspirin-induced asthma Bronchial hyper-reactivity Urticaria Angioedema No requirement for sodium warfarin or other anticoagulant No frequent (greater than 36 times/year) NSAID use within the past 5 years No recurrent arthritis or other musculoskeletal problems No narcotic or alcohol dependency (unless there has been at least a 6-month period of abstinence) No prior or concurrent malignancy within 5 years (including metastases) except nonmelanomatous skin cancer No pregnant or nursing women Effective contraception required of fertile women~PRIOR CONCURRENT THERAPY: No concurrent enrollment in a colon cancer treatment trial or other chemoprevention trial Biologic therapy: At least 6 months since immunosuppressive therapy (i.e., azathioprine, methotrexate, cyclosporine) Chemotherapy: Prior chemotherapy allowed for patients with Dukes' B2/C colorectal cancer No concurrent chemotherapy Endocrine therapy: Prior non-immunosuppressive steroid treatment allowed Radiotherapy: Prior radiotherapy allowed for patients with Dukes' B2/C colorectal cancer No concurrent radiotherapy Surgery: Curative resection required

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Aspirin (Type: EXPERIMENTAL): 325 mg/day PO
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance of Platelet Inhibition With Cangrelor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* 18 Years of Age~* Non emergent coronary bypass graft surgery~* Received a thienopyridine within 48 hours prior to enrollment~Exclusion Criteria:~* Confirmed or suspected pregnancy~* Cerebrovascular accident within one yar~* Intracranial neoplasm~* History of bleeding diathesis~* Thrombocytopenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Cangrelor (Type: EXPERIMENTAL): Cangrelor was administered as a continuous IV infusion of 0.75µg/kg/min for a minimum of 48 hours and a maximum of 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): A placebo infusion was administered as a continuous IV infusion of 0.75µg/kg/min for a minimum of 48 hours and a maximum of 7 days, to maintain the blind.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~At dosing week 24 of protocol CL0600-004 (NCT00081458), subjects will be reviewed for their participation in this study.~Subjects who meet all of the following criteria can be enrolled in this study:~* Signed and dated informed consent form (ICF) to participate before any study-related procedures are performed~* Completion of protocol CL0600-004 (NCT00081458)~Exclusion Criteria:~* History of cancer or clinically significant lymphoproliferative disease with fewer than 5 years documented disease-free state~* History of alcohol or drug abuse (within previous year)~* Prior use of native glucagon-like peptide 2 (GLP-2) within 3 months of screening visit~* Pregnant or lactating women~* Any condition or circumstance, which in the investigator's opinion would put the subject at any undue risk, prevent completion of the study, or interfere with analysis of the study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- teduglutide 0.05 mg/kg/d (Type: EXPERIMENTAL): 0.05 mg/kg/d teduglutide subcutaneous injection
- teduglutide 0.10 mg/kg/d (Type: EXPERIMENTAL): 0.10 mg/kg/d teduglutide subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed HIV positive after voluntary counselling and testing~* Aged between 18 and 60 years of age~* Antiretroviral treatment naive~* CD4+ cell count of \<200 cells/mm3 at the time of TB diagnosis~* ALT \<5 times ULN~* Serum creatinine \<1.4 mg/dl~* Haemoglobin \>8 mg/L~* TB diagnosis; either probable (clinical symptoms plus chest x-ray and response to anti-TB medication) or definitive( sputum AFB culture confirmed) and receiving or planning to receive rifampicin-containing anti-TB therapy for at least a 2 week period before the initiation of ART~* No other active OI (CDC class C event)~* Able to provide written informed consent~Exclusion Criteria:~* Current use of steroids and other immunosuppressive agents~* Current use of any prohibited medications related to compliance and drug pharmacokinetics~* Patients with current alcohol or illicit substance use that in the opinion of the site Principal Investigator would conflict with any aspect of the conduct of the trial.~* Previous exposure to nevirapine monotherapy~* Unlikely to be able to remain in follow-up for the protocol defined period~* Patients with proven or suspected acute hepatitis. Patients with chronic viral hepatitis are eligible provided ALT, AST \< 5 x ULN.~* Karnofsky performance score \<30%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): IDV/r 600/100 mg + rifampicin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-75~* Increased number of respiratory tract infections~* At least 42 days of infections during 2008 or 2009~* S-25 OH vitamin D3 \< 250 nM~* Not planning a pregnancy during the coming year~* Accepting the use of contraceptives during 1 year~Exclusion Criteria:~* Continuous antibiotic treatment~* Hypercalcemia~* Sarcoidosis~* Kidney disease~* Tuberculosis~* Pregnancy~* Kidney stone~* Heart medication (glycosides)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Vitamin D (Type: ACTIVE_COMPARATOR): Vigantol (cholecalciferol) 4000 IE/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed infiltrating breast adenocarcinoma~  * Large, operable tumor~ * Stage T2 (≥ 3 cm) or T3-T4 (excluding inflammatory disease), N0-N3, M0 disease~    * No bilateral inflammatory breast tumors (T4d \[PEV-2 or PEV-3\])~ * Elston-Ellis grade I or II and mitotic index 1 or 2 (if \< 65 years of age)~* At least 1 embedded and 1 frozen biopsy sample available~* No multifocal or multicentric tumors for which breast conservation cannot be envisaged~* No ErbB2-overexpressing tumors (HER2 3+ by IHC OR HER2 2+ by IHC and FISH positive)~* Hormone receptor status:~  * Estrogen receptor and/or progesterone receptor positive tumor (\> 10%) as assessed by IHC~PATIENT CHARACTERISTICS:~* Female~* Postmenopausal~* ECOG performance status 0-2~* ANC ≥ 2,000/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 10 g/dL~* Creatinine ≤ 1.5 times upper limit of normal (ULN)~* Total bilirubin ≤ 1.25 times ULN~* AST and ALT ≤ 1.5 times ULN~* Alkaline phosphatase ≤ 2.5 times ULN~* No other cancer within the past 10 years, except basal cell skin cancer or previously treated carcinoma in situ of the cervix~* No uncontrolled cardiac pathology, including any of the following:~  * Angina pectoris~ * Congestive cardiac insufficiency~ * Myocardial infarction within the past 3 months~* No known history of hemorrhagic diathesis~* No known allergy to the study drugs or their excipients~* No congenital galactosemia, glucose malabsorption syndrome, or lactase deficiency~* No chronic somatic or psychiatric illness with pejorative prognosis~* No geographical, social, or psychiatric condition that would preclude study compliance and follow-up schedule~* No individual deprived of liberty or placed under the authority of a tutor~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy, hormonal therapy, or any targeted treatment for the breast tumor~* At least 2 weeks since prior hormone replacement therapy for menopause~* No concurrent long-term anticoagulation treatment~* No concurrent participation on another therapeutic trial involving an experimental molecule

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Anastrozole
- Arm B (Type: EXPERIMENTAL): Fulvestrant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Accent Cardiac MRI Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Have an approved indication per American College of Cardiology(ACC)/ American Heart Association(AHA)/ Heart Rhythm Society(HRS)/ European Society of Cardiology(ESC) guidelines for implantation of a pacemaker~* Will receive a new dual chamber pacemaker and leads~* Be willing to undergo an elective MRI scan without complete sedation, that is ,under consciousness during MRI scan~* Be able to provide informed consent for study participation~* Be willing and able to comply with the prescribed follow-up tests and schedule of evaluations~* Is not contraindicated for an MRI scan (per the pre-MRI safety screening form)~* Age≥18 years~* Subjects must be able to undergo pectoral implantation~Exclusion Criteria~* Having an existing pacemaker or Implantable Cardioverter Defibrillator (ICD) .A new pacemaker and lead is required for enrollment~* Permanent Atrial Fibrillation/Flutter~* Are medically indicated for an MRI scan at the time of enrollment~* Have an existing active implanted medical device, e.g. neurostimulator, infusion pump etc~* Have a non-MRI compatible device or material implanted~* Have a lead extender or adaptor~* Be unable to fit in MRI bore; will come into contact with the magnet façade inside the MRI bore~* Are currently participating in a clinical investigation that includes an active treatment arm~* Are allergic to dexamethasone sodium phosphate(DSP)~* Are pregnant or planning to become pregnant during the duration of the study~* Have a life expectancy of less than 12 months due to any condition~* Subjects with exclusion criteria required by local law (e.g. age)~* Are unable to comply with the follow up schedule

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cardiac MRI Scan Group (Type: EXPERIMENTAL): None
- Control Group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Accolade® TMZF® Hip Stem Outcomes Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is a candidate for a primary total hip replacement.~2. Patient has primary diagnosis of osteoarthritis (OA).~3. Male and non-pregnant female patients ages 18 to 90.~4. Patient has signed an Institutional Review Board (IRB) approved, study specific Informed Patient Consent Form.~5. Patient willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation.~6. Patient capable of undergoing a pre-op central DXA (dual-energy x-ray absorptiometry) scan for a bone mineral density (BMD) reading.~Exclusion Criteria:~1. Patient has an active infection within the affected hip joint.~2. Patient requires a revision surgery of a previously implanted total hip arthroplasty or hip fusion to the affected joint.~3. Patient who is morbidly obese, Body Mass Index (BMI) \> 40.~4. Patient has a neuromuscular or neurosensory deficiency, which limits ability to evaluate the safety and efficacy of the device.~5. Patient has the following diagnosed systemic diseases: Paget's disease, renal osteodystrophy, lupus erythematosus, rheumatoid arthritis, metabolic bone disease and sickle cell anemia.~6. Patient is immunologically suppressed or receiving chronic steroids more than 30 days. Patients receiving oral or IV steroids within one month of surgery.~7. Patient is a prisoner.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Accolade® TMZF® Hip Stem (Type: OTHER): Accolade® TMZF® Hip Stem Study Device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Invasive Coronary Angiography. Men or Women age 18 or older - see protocol for additional details.~Exclusion Criteria:~Women who are pregnant, lactating, or of child bearing potential who are not practicing birth control.~Unstable cardiac status. History of coronary artery bypass graft. History of percutaneous coronary intervention within the past six months. See protocol for additional details.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Flurpiridaz F18 (Type: EXPERIMENTAL): Open-label study of a single dose of Flurpiridaz F18 injection for PET MPI compared to a single dose of 99mTc sestamibi or tetrofosmin for SPECT MPI in patients with suspected or known coronary artery disease referred for coronary catheterization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Participant is healthy, as determined by medical history and physical examination.~* Participant is 2 years to \< 5 years of age at the time of vaccination.~* At least one year from primary vaccination with a monovalent meningococcal C conjugate vaccine has elapsed.~* Parent/Guardian has signed an Ethics Committee-approved informed consent form. A culturally appropriate translation will be used for non-English speaking participants where required.~Exclusion Criteria :~* Serious chronic disease (i.e. cardiac, renal, neurologic, metabolic, rheumatologic, etc.)~* Known or suspected impairment of immunologic function~* Acute medical illness with or without fever within the last 72 hours or an axillary temperature ≥ 37.5ºC at the time of inclusion~* History of documented invasive meningococcal disease~* Administration of immune globulin, other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrolment~* Antibiotic therapy within the 72 hours prior to vaccination or 72 hours prior to drawing any blood sample~* Received any vaccine in the 28-day period prior to enrolment, or scheduled to receive any vaccine during enrolment in the trial~* Received a meningococcal C conjugate vaccine within one year prior to enrolment~* Suspected or known hypersensitivity to any of the vaccine components~* Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures~* Enrolled in another clinical trial~* Any condition, which, in the opinion of the investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 4 Years
- Healthy Volunteers: t

Study Arms:
- Menactra® Vaccine Group (Type: EXPERIMENTAL): Participants receiving the tetravalent (A, C, Y, and W 135) meningococcal diphtheria toxoid conjugate vaccine
- Hiberix® Vaccine Group (Type: ACTIVE_COMPARATOR): Participants receiving Haemophilus Influenzae Type b (Hib) vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients HIV positive \> 18 years.~* Patients in treatment with Sustiva(r)+Truvada(r); or Sustiva (r)+Kivexa(r).~* HIV-ARN \< 50 copies/mL in the las six months.~* Clinically evident lipoatrophy (moderate or severe).~* Negative pregnancy test.~* Signed informed consent.~Exclusion Criteria:~* Evidence of failure or mutation to therapy with protease inhibitors.~* Patients that can not be treated with LPV/r.~* Mild lipoatrophy.~* History of alcoholism or drug addiction that discourages participation in the study.~* Pregnancy or breastfeeding.~* Documented current or 4 weeks prior opportunistic infection.~* Creatinin clearance \< 60mL/min.~* Concomitant use of nephrotoxic drugs or immunosuppressants.~* Actual treatment with systemic corticosteroids, IL-2 or chemotherapy.~* Patients under treatment with other drugs in investigation.~* Acute hepatitis.~* Any other disease that discourages participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EFV and Fixed combinations of analogues (Type: ACTIVE_COMPARATOR): EFV + Fixed combinations of analogue tenofovir + emtricitabine, or abacavir + lamivudine
- LPV/r and combination of analogues. (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transcutaneous Electrical Nerve Stimulation for Pain Relief During the Active Phase of Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* primigravida~* literate~* A single fetus in vertex position~* Low-risk Pregnancy~* From 37 weeks of gestation~* Cervical dilatation between 4 and 5 cm with uterine dynamics normal for this stage~* Labor in early spontaneous~* No use of medications during the study period~* Absence of cognitive or psychiatric problems~* Intact membranes~* No risk factors associated~* Who wish to participate and signed the informed consent~Exclusion Criteria:~* TENS procedure intolerance~* Use of any medication or procedure that promotes pain relief~* Use of pacemaker

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Experimental TENS (Type: EXPERIMENTAL): TENS Intervention Group(GIE) used for 30 minutes, during uterine contractions between 4-5 cm
- control Group (Type: NO_INTERVENTION): Formed by mothers who will not use EAC to receive the routine procedures of motherhood, but will be monitored and evaluated at the same time in the intervention group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete